Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SGN-40 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| bortezomib | DRUG | Escalating intravenous repeating dose |
| SGN-40 | DRUG | Escalating intravenous repeating dose |
Inclusion Criteria: * Age ≥ 18 years * Documented pathologic diagnosis of multiple myeloma that has relapsed or failed to respond after treatment with at least one prior systemic therapy (other than corticosteroid monotherapy) * Measurable disease * At least one prior systemic therapy other than si...
Top 20 of 25 competitors
SGN-40 was studied as a treatment for relapsed or refractory multiple myeloma, a cancer of plasma cells in the bone marrow. It was evaluated in combination with bortezomib in patients whose disease had returned or stopped responding to prior therapy. SGN-40 remains an investigational agent and has not been approved for commercial use.
SGN-40 is being developed by Roche Holding AG, which trades over the counter under the ticker RHHBY. Roche holds the development program for this oncology asset.
SGN-40 is in Phase 1 clinical development. It has completed one Phase 1 trial in multiple myeloma and is not currently listed as having any active trials. It is an investigational drug and has not received FDA approval.
SGN-40 has been evaluated in one completed clinical trial, NCT00664898, titled A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma. The Phase 1 study enrolled 18 patients and was uncontrolled, non-randomized, and not blinded.